Study to evaluate immunotherapy in combination with radiation in prostate cancer patients
Number: NCT01436968 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Advantagene, Inc. Sponsor Trial Information Trial Location(s) and Contact(s) |
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Number: NCT02346253 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Stanford University|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Number: NCT02643303 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Ludwig Institute for Cancer Research|MedImmune LLC|Cancer Research Institute, New York City Sponsor Trial Information Trial Location(s) and Contact(s) |
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
Number: NCT02713269 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
Number: NCT02913131 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Rahul Aggarwal|National Institutes of Health (NIH)|National Cancer Institute (NCI)|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s) |
Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate
Number: NCT02944201 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Montefiore Medical Center|Albert Einstein College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s) |
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Number: NCT02946996 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Medical University of South Carolina Sponsor Trial Information Trial Location(s) and Contact(s) |
Apalutamide With or Without Abiraterone, Hormone, and Prednisone in Treating High-Risk Patients Undergoing Surgery
Number: NCT02949284 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Number: NCT02960022 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of Androgen Treatment in High-Risk Biochemically Relapsed Prostate Cancer
Number: NCT03009981 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: 3 Sponsor(s): Alliance Foundation Trials, LLC.|Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s) |
Clinical Study of change in brain structure or activity in men treated with androgen receptor therapies such as abiraterone acetate and enzalutamide
Number: NCT03016741 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s) |
Study of Olaparib in Men With High-Risk Recurrent Prostate Cancer Following Prostate Surgery
Number: NCT03047135 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study to Evaluate Relugolix in Men With Advanced Prostate Cancer
Number: NCT03085095 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Myovant Sciences GmbH Sponsor Trial Information Trial Location(s) and Contact(s) |
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
Number: NCT03150810 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): BeiGene|Myriad Genetics, Inc. Sponsor Trial Information Trial Location(s) and Contact(s) |
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Number: NCT03170960 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Exelixis Sponsor Trial Information Trial Location(s) and Contact(s) |
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Number: NCT03181867 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s) |
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Number: NCT03333616 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dana-Farber Cancer Institute|Bristol-Myers Squibb Sponsor Trial Information Trial Location(s) and Contact(s) |
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel
Number: NCT03419234 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Sponsor Trial Information Trial Location(s) and Contact(s) |
To evaluate whether olaparib can reduce prostate cancer with defects in DNA repair genes when olaparib is given for approximately 3 months before surgery
Number: NCT03432897 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Dr Anthony Mega|Rhode Island Hospital|The Miriam Hospital|AstraZeneca|Brown University Sponsor Trial Information Trial Location(s) and Contact(s) |
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Number: NCT03436654 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s) |
Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
Number: NCT03439033 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University Sponsor Trial Information Trial Location(s) and Contact(s) |
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Number: NCT03471650 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s) |
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
Number: NCT03541850 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Number: NCT03541928 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): The Methodist Hospital System Sponsor Trial Information Trial Location(s) and Contact(s) |
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Number: NCT03565835 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Montefiore Medical Center Sponsor Trial Information Trial Location(s) and Contact(s) |
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Number: NCT03570619 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Cancer Center|Memorial Sloan Kettering Cancer Center|University of California, San Francisco Sponsor Trial Information Trial Location(s) and Contact(s) |
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
Number: NCT03581500 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of Nivolumab in Patients With High-Risk Recurrent Prostate Cancer
Number: NCT03637543 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Beth Israel Deaconess Medical Center|Bristol-Myers Squibb|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s) |
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Number: NCT03678025 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Southwest Oncology Group|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Number: NCT03706365 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Eli Lilly and Company Sponsor Trial Information Trial Location(s) and Contact(s) |
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
Number: NCT03707184 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)
Number: NCT03748641 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of Pembrolizumab Plus Androgen Receptor Targeting Prior to Prostatectomy for High Risk Patients
Number: NCT03753243 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Merck Sharp & Dohme Corp.|Astellas Pharma Inc|Portland VA Medical Center Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of Apalutamide in Participants With High Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Number: NCT03767244 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s) |
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Number: NCT03777982 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s) |
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
Number: NCT03787680 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s) |
(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes
Number: NCT03796195 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): Northwestern University Sponsor Trial Information Trial Location(s) and Contact(s) |
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
Number: NCT03821792 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Number: NCT03824275 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2| Phase 3 Sponsor(s): Columbia University Sponsor Trial Information Trial Location(s) and Contact(s) |
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Number: NCT03833921 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Martha Mims|Baylor College of Medicine Sponsor Trial Information Trial Location(s) and Contact(s) |
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Number: NCT03860987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s) |
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Number: NCT03899987 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Roswell Park Cancer Institute|National Cancer Institute (NCI)|Hemispherx Biopharma Sponsor Trial Information Trial Location(s) and Contact(s) |
A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer
Number: NCT03910660 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): BioXcel Therapeutics Inc Sponsor Trial Information Trial Location(s) and Contact(s) |
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Number: NCT03951831 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Mark Stein|Regeneron Pharmaceuticals|Columbia University Sponsor Trial Information Trial Location(s) and Contact(s) |
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
Number: NCT03964337 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Duke University|Exelixis Sponsor Trial Information Trial Location(s) and Contact(s) |
Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer
Number: NCT03976843 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Sponsor Trial Information Trial Location(s) and Contact(s) |
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
Number: NCT03987386 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Number: NCT03999515 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Washington|National Cancer Institute (NCI)|Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Number: NCT04019327 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center Sponsor Trial Information Trial Location(s) and Contact(s) |
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
Number: NCT04020094 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of Utah|Bavarian Nordic|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s) |
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Number: NCT04030559 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): University of California, Davis|National Cancer Institute (NCI)|Janssen, LP Sponsor Trial Information Trial Location(s) and Contact(s) |
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
Number: NCT04037358 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sponsor Trial Information Trial Location(s) and Contact(s) |
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Number: NCT04126070 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Xiao X. Wei|Bristol-Myers Squibb|Dana-Farber Cancer Institute Sponsor Trial Information Trial Location(s) and Contact(s) |
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
Number: NCT04134208 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 4 Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
Number: NCT04134260 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): NRG Oncology|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Number: NCT04157088 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Bayer Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes
Number: NCT04171700 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Clovis Oncology, Inc. Sponsor Trial Information Trial Location(s) and Contact(s) |
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)
Number: NCT04186819 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Blue Earth Diagnostics|Parexel Sponsor Trial Information Trial Location(s) and Contact(s) |
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Number: NCT04191096 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Merck Sharp & Dohme Corp. Sponsor Trial Information Trial Location(s) and Contact(s) |
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
Number: NCT04194554 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): University of Michigan Rogel Cancer Center|Janssen Scientific Affairs, LLC Sponsor Trial Information Trial Location(s) and Contact(s) |
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients
Number: NCT04246671 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Bavarian Nordic Sponsor Trial Information Trial Location(s) and Contact(s) |
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
Number: NCT04253483 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Number: NCT04262154 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Memorial Sloan Kettering Cancer Center|Genentech, Inc. Sponsor Trial Information Trial Location(s) and Contact(s) |
Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer
Number: NCT04267887 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Oregon Health and Science University Sponsor Trial Information Trial Location(s) and Contact(s) |
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Number: NCT04383210 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Elevation Oncology Sponsor Trial Information Trial Location(s) and Contact(s) |
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
Number: NCT04390880 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): VA Greater Los Angeles Healthcare System Sponsor Trial Information Trial Location(s) and Contact(s) |
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Number: NCT04402151 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Weill Medical College of Cornell University|National Cancer Institute (NCI) Sponsor Trial Information Trial Location(s) and Contact(s) |
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications
Number: NCT04423029 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Dragonfly Therapeutics Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Subjects With Malignant Solid Tumors
Number: NCT04424641 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 1|Phase 2 Sponsor(s): Genmab Sponsor Trial Information Trial Location(s) and Contact(s) |
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
Number: NCT04457245 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): Jonsson Comprehensive Cancer Center|Progenics Pharmaceuticals, Inc. Sponsor Trial Information Trial Location(s) and Contact(s) |
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
Number: NCT04493853 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 3 Sponsor(s): AstraZeneca Sponsor Trial Information Trial Location(s) and Contact(s) |
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Number: NCT04523207 PHEN Patient Summary ClinicalTrials.gov Information Trial Phase: Phase 2 Sponsor(s): Janssen Research & Development, LLC Sponsor Trial Information Trial Location(s) and Contact(s) |